PRAME and breast carcinoma: Based on the increased expression of PRAME in breast tumours, especially basal‐like and luminal B tumours (Figure S1A‐B), we interrogated the TCGA breast cancer cohort to assess the prognostic connotation of PRAME tumour expression (Figure 1A).